Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis

A method of reducing fibrosis in the tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGF-β1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine co-polymer,

• wherein said composition comprises the siRNA molecule hmTF-25-2:
• sense, 5′-r(CCCAAGGGCUACCAUGCCAACUUCU)-3′ (SEQ ID NO:
• 1), antisense, 5′-r(AGAAGUUGGCAUGGUAGCCCUUGGG)-3′ (SEQ ID NO:
• 2), and the siRNA molecule hmCX-25-1:
• sense, 5′-r(GGUCUGGUGCCUGGUCUGAUGAUGU)-3′ (SEQ ID NO:
• 3), antisense, 5′-r(ACAUCAUCAGACCAGGCACCAGACC)-3′ (SEQ ID NO:
• 4).